| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
CP-312 targets the antioxidant response network by inducing the expression of HMOX1, the gene encoding heme oxygenase-1 (HO-1). HO-1 is a cytoprotective enzyme that catalyzes the degradation of heme, producing biliverdin, carbon monoxide, and ferrous iron, all of which have antioxidant and anti-inflammatory properties. By upregulating HO-1, CP-312 enhances the cellular defense against oxidative stress.
|
|---|---|
| ln Vitro |
CP-312 (10 µM; 2 hours) demonstrated good effectiveness with an EC50 = 6.7 µM in preventing acute peroxide-induced cell death in hiPSC-CM shells [1].
In vitro, CP-312 protects hiPSC-CM viability from oxidative stress. It induces the expression of HMOX1, leading to increased HO-1 levels. This protects the cardiomyocytes from damage caused by reactive oxygen species. The compound's ability to activate the antioxidant response network makes it a valuable tool for studying cardioprotection and oxidative stress. |
| ln Vivo |
CP-312 has been shown to protect human iPSC-derived cardiomyocytes from oxidative stress in vitro. Its in vivo activity is implied by its cardioprotective mechanism, but specific in vivo study details are not well-documented. As an inducer of HO-1, it is expected to have protective effects in animal models of oxidative stress-related diseases, such as ischemia-reperfusion injury.
|
| Enzyme Assay |
CP-312 is evaluated in cell-free assays to measure its ability to induce HO-1 activity. However, specific enzymatic or receptor binding assays are not well-documented. Its purity and identity can be confirmed using HPLC and NMR analysis. The compound's ability to activate antioxidant response elements can be assessed using biochemical assays.
|
| Cell Assay |
CP-312 is assessed in cell-based assays using hiPSC-CMs. Cells are treated with CP-312, and the expression of HMOX1 is measured by qPCR or Western blot analysis. Cell viability under oxidative stress conditions is assessed to determine the compound's protective effects. These assays help to confirm its mechanism of action as an HO-1 inducer.
|
| Animal Protocol |
CP-312 is administered in animal models to evaluate its cardioprotective effects. It has been studied in models of cardiac ischemia-reperfusion injury or other conditions involving oxidative stress. Efficacy is assessed by measuring infarct size, cardiac function, and markers of oxidative damage. However, specific animal study protocols are not extensively documented.
|
| ADME/Pharmacokinetics |
CP-312 has a molecular weight of 361.86. Its CAS number is 895470-67-4. The compound is soluble in DMSO and has a purity of 98% by HPLC. Its chemical name is 2-((4-chlorophenyl)thio)-N-(4-(pyridin-2-yl)thiazol-2-yl)acetamide. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CP-312. The compound is for research use only and is not intended for human therapeutic use. It is a potent HO-1 inducer and is used to study cardioprotection and oxidative stress.
|
| References |
[1]. Kirby RJ, et, al. Discovery of Novel Small-Molecule Inducers of Heme Oxygenase-1 That Protect Human iPSC-Derived Cardiomyocytes from Oxidative Stress. J Pharmacol Exp Ther. 2018 Jan;364(1):87-96.
|
| Additional Infomation |
CP-312 is a potent inducer of heme oxygenase-1 (HO-1). It is also known as Cardioprotectant 312. It protects human iPSC-derived cardiomyocytes from oxidative stress. The compound is not approved for clinical use and is intended for research purposes only.
|
| Molecular Formula |
C16H12CLN3OS2
|
|---|---|
| Molecular Weight |
361.868979454041
|
| Exact Mass |
361.011
|
| Elemental Analysis |
C, 53.11; H, 3.34; Cl, 9.80; N, 11.61; O, 4.42; S, 17.72
|
| CAS # |
895470-67-4
|
| PubChem CID |
22581391
|
| Appearance |
Solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
394
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KAWIOCMUARENDQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12ClN3OS2/c17-11-4-6-12(7-5-11)22-10-15(21)20-16-19-14(9-23-16)13-3-1-2-8-18-13/h1-9H,10H2,(H,19,20,21)
|
| Chemical Name |
2-(4-chlorophenyl)sulfanyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide
|
| Synonyms |
CP312; CP 312; CP-312
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7634 mL | 13.8171 mL | 27.6342 mL | |
| 5 mM | 0.5527 mL | 2.7634 mL | 5.5268 mL | |
| 10 mM | 0.2763 mL | 1.3817 mL | 2.7634 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
